No effect of Implanon® on inflammatory cardiovascular parameters

References

• Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility. 2005;861–942.
   Google Scholar
• Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:2890.
   PubMed Web of Science ®Google Scholar
• Doring A, Frohlich M, Lowel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004;172:281–286.
   PubMed Web of Science ®Google Scholar
• Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol 1999;180:S357–S363.
   Google Scholar
• Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:67–73.
   PubMedGoogle Scholar
• Nishida M, Moriyama T, Ishii K, Takashima S, Yoshizaki K, Sugita Y, Yamauchi-Takihara K. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta 2007;384:99–104.
   PubMed Web of Science ®Google Scholar
• Kunnari A, Santaniemi M, Jokela M, Karjalainen AH, Heikkinen J, Ukkola O, Kesaniemi YA. Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. Metabolism 2008;57:1509–15.
   PubMedGoogle Scholar
• Djurovic S, Os I, Hofstad AE, Abdelnoor M, Westheim A, Berg K. Increased plasma concentrations of TGF-β1 after hormone replacement therapy. J Intern Med 2000;247:279–285.
   PubMedGoogle Scholar
• Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642–672.
   PubMed Web of Science ®Google Scholar
• Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005;52:111–118.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, Ruokonen A, Leinonen M, Laitinen J, Jarvelin MR, Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol 2008;199:529e1–529e10.
   Google Scholar
• White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293–296.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf) 2008;68:355–360.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on transforming growth factor beta1 and endothelin-1. Horm Metab Res 2008;40:692–669.
   PubMedGoogle Scholar
• Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990;7:147–159.
   PubMedGoogle Scholar
• Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763–771.
   PubMed Web of Science ®Google Scholar
• Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49:1455–1461.
   PubMed Web of Science ®Google Scholar
• Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ 1991;303:694.
   PubMed Web of Science ®Google Scholar
• Kip KE, Marroquin OC, Shaw LJ, Arant CB, Wessel TR, Olson MB, Johnson BD, Mulukutla S, Sopko G, Merz CN, Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J 2005;150:900–906.
   PubMed Web of Science ®Google Scholar
• Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 2006;119:167 e1–167 e8.
   Google Scholar
• Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24–38.
   PubMed Web of Science ®Google Scholar
• Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643–650.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008;93:1702–1710.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 2005;8:317–326.
   PubMed Web of Science ®Google Scholar
• Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sa MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;80:519–526.
   PubMed Web of Science ®Google Scholar
• Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008;34:12–18.
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Alvarez-Blasco F, Escobar-Morreale HF. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity (Silver Spring) 2009;17:3–9.
   PubMedGoogle Scholar
• Tonstad S, Thorsrud H, Torjesen PA, Seljeflot I. Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease? Metabolism 2007;56:260–266.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007;27:2094–2099.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004;69:271–278.
   PubMed Web of Science ®Google Scholar